Takeda and Amylin take obesity combo forward as davalintide dropped
This article was originally published in Scrip
Executive Summary
Takeda and Amylin Pharmaceuticals have selected a combination of pramlintide and metreleptin for Phase III development for obesity following disappointing results with davalintide, another candidate being investigated under the two firms' global alliance for the indication.